Kyowa Hakko Kirin Emphasizes Efforts On Kidney Disease With DPP-4
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin President Nobuo Hanai announced July 27 at a financial results briefing in Tokyo that the company will continue to provide a wide range of products targeting chronic kidney disease, with focus on renal anemia drugs NESP and ESPO.